Administer intravenously. The bolus is usually given over 1-2 minutes, followed by continuous infusion using an infusion pump. Must not be mixed with other drugs or administered via the same IV line without flushing.

Eptifibatide binds reversibly to the platelet glycoprotein IIb/IIIa receptor, the final common pathway for platelet aggregation. This binding prevents fibrinogen and other adhesive ligands from binding to the receptor, thereby inhibiting platelet cross-linking and aggregation.

• •History of bleeding diathesis or active pathological bleeding within 30 days (e.g., gastrointestinal bleeding, intracranial hemorrhage)
• •Major surgery within 6 weeks
• •Stroke within 30 days or any history of hemorrhagic stroke
• •Severe uncontrolled hypertension (systolic BP >200 mmHg or diastolic BP >110 mmHg) resistant to antihypertensive therapy
• •Prior exposure to eptifibatide with development of thrombocytopenia
• •Concomitant use of another parenteral GP IIb/IIIa inhibitor
• •Renal dialysis

Store at 2°C to 25°C (36°F to 77°F). Protect from light. Do not freeze.

Overdose may lead to increased bleeding complications. Management involves immediate discontinuation of eptifibatide, close monitoring of bleeding, and supportive care. Platelet transfusions may be considered in severe cases of thrombocytopenia or life-threatening bleeding.

Pregnancy Category B. Studies in animals have shown no evidence of fetal harm, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. It is not known whether eptifibatide is excreted in human milk; caution should be exercised when administered to a nursing woman.